MENU
MAY 10, 2017 5:00 AM PDT

Complete workflow solution from gene-to-protein combine highly advanced expression systems with expression optimized genes

Speaker
  • Manager, Manufacturing , Thermo Fisher Scientific
    Biography
      Dr. Fath is a Manager, Manufacturing in the Biosciences Division at Thermo Fisher Scientific, GeneArt in Germany. Stephan received his PhD in protein biochemistry from the University of Heidelberg, Germany. After his education and research work on ribosomal biogenesis, he joined Memorial Sloan Kettering Cancer Center / New York, USA as a Research Fellow, studying COP II proteins by protein crystallography. Stephan has a strong background in protein biochemistry, expertise in different protein expression systems and a proven track record of publishing his scientific work in internationally renowned journals. In 2008 he joined GeneArt and worked as Senior Scientist in R&D before switching to Operations. As Manager, Manufacturing he is currently responsible for the highly customized protein expression & purification services.

    Abstract

    Reliable autologous expression of recombinant human proteins - from gene sequence to the expressed and purified protein - in human or CHO cells is essential for many aspects of biomedical research and drug development, but often hampered by low expression yields limiting subsequent structural and functional analyses.

    Thermo Fisher Scientific’s complete portfolio from Invitrogen™ GeneArt™ gene synthesis to advanced expression systems provides researchers the unique ability to optimize their gene expression results. Our proprietary sequence optimization GeneOptimizer™ algorithm improves the sequence via a parallel multi-parameter approach. To further maximize the protein yield, you can choose between our best-in-class serum free Gibco™ FreeStyle™ or Invitrogen™ Expi293™ and ExpiCHO™ expression host systems.

    This holistic approach is the most efficient way to streamline your gene-to-protein workflow for maximal performance, either by purchasing reagents for in-house work or by outsourcing the complete workflow as a highly customized service offered by the GeneArt™ Protein Team.

    The talk will explain the basis of gene synthesis and optimization and how the combination with the best expression system generates unmatched expression reliability and protein yields. This approach is highly advantageous early on during drug development to minimize changes in protein quality/function when moving from R&D to bioproduction.


    Show Resources
    MAY 10, 2017 5:00 AM PDT

    Complete workflow solution from gene-to-protein combine highly advanced expression systems with expression optimized genes


    Specialty

    Cancer Research

    Biotechnology

    Cell Biology

    Molecular Biology

    Cell Culture

    Immunology

    Drug Discovery

    Antibodies

    Cancer Therapeutics

    Genetics

    Biomarkers

    Microbiology

    Crispr-Cas9

    Gene Expression

    Clinical Diagnostics

    Geography

    North America34%

    Europe27%

    Asia21%

    South America10%

    Africa8%

    Registration Source

    Website Visitors100%

    Job Title

    Student32%

    Research Scientist15%

    Post Doc10%

    Scientist9%

    Educator/Faculty7%

    Facility/Department Manager7%

    Executive6%

    Medical Laboratory Technician5%

    Marketing/Sales3%

    Clinical Laboratory Scientist2%

    Chemist2%

    Medical Doctor/Specialist1%

    Biologist1%

    Organization

    Biotech Company10%

    Academic Institution9%

    Research Institute6%

    Life Science Company5%

    Clinical Laboratory4%

    Government4%

    Medical School3%

    Hospital2%

    Veterinary School2%

    Ambulatory Care2%

    Media1%

    Manufacturer - Other1%

    Diagnostic Company1%

    Pharmaceutical Company1%

    Other4%


    Show Resources
    Show Resources
    Attendees
    • See more
    Connect with us